FA tells me they haven't sold much due to the age demographic limitation of wheezo even in a small market like Australia (given pharmacies will be the same worldwide) so this quarterly revenue will be well below what the market is expecting especially given the $6-8M revenue guideline RSH has stated to the market and normally when a company miss their own guideline by a lot the pps will get smashed more by the market so they only have 1 month to turn this around with more sale or news.....
RSH Price at posting:
14.5¢ Sentiment: Hold Disclosure: Held
